/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | QNRXQuoin Pharmaceutical |
|---|---|
| Last close | $4.02close 2026-11-04 |
| Change % | +2.29%close 2026-11-04 |
| Market cap | $283Mclose 2026-11-04 |
| P/E | no EPS filed |
| Revenue | $0⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerExcludingAssessedTax As ofFY ending 2021-12-31 Filing20-F · 0001104659-22-045620 · filed 2022-04-14 Open the filing on EDGAR →Open the XBRL payload →CiteQuoin Pharmaceuticals Ltd. (QNRX), us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax: 0 USD, fiscal year ended 2021-12-31. Form 20-F, accession 0001104659-22-045620, filed 2022-04-14. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001671502/us-gaap/RevenueFromContractWithCustomerExcludingAssessedTax.json |
| Rev growth (YoY) | no prior year filed |
| Net income | $-15800000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 FilingDEF 14A · 0001104659-26-084078 · filed 2026-07-16 Open the filing on EDGAR →Open the XBRL payload →CiteQuoin Pharmaceuticals Ltd. (QNRX), us-gaap:NetIncomeLoss: -15,800,000 USD, fiscal year ended 2025-12-31. Form DEF 14A, accession 0001104659-26-084078, filed 2026-07-16. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001671502/us-gaap/NetIncomeLoss.json |
| Net margin | periods differ |
| EPS (diluted) | no EPS filed |
| Piotroski F-ScoreUNVALIDATED | 1FY to 2021-12-31, older period |
| Altman Z-ScoreUNVALIDATED | inputs not filed |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | open now |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.